Cohorts
01 / 14

TriStar Technology Group

Quality biospecimens
& data for precision medicine

FFPE surgical samples — Primary tumors, Mets, Normal (non-malignant) tissues

Donors from UK, Italy, France with informed consent & ethics approval

Clinical follow-up data including treatment, response, OS & PFS

Responders & non-responders to SOC treatment including CKI/IO

Mutations, fusions and other diagnostic markers

Expert IHC capabilities — over 100 optimized assays

02 / 14

Breadth of donor profiles.

Specimen, treatment, outcomes, and molecular data — structured at the patient level.

Patient trajectory

Primary & matched distant mets Matched normal tissue Neoadjuvant › adjuvant › SOC targeted & CKI/IO

Outcomes, structured

Overall Survival (months) Progression-Free Survival (months) Time to events (TTE months) Recurrence date Death date Last follow-up Event flags (recurrence / death / composite)

Molecular characterization

IHC FISH RNA-ISH NGS: SNV, CNV, Fusions

Records are fully anonymized. Not every patient has every field populated, and not every project needs every field. Cohorts are pulled to fit the project; populated fields reflect real-world clinical practice at the source center.

See an example record
03 / 14

Cohorts available.

Tumor types crossed with the cohort designs we maintain.

Jump to cohort detail
Tumor type Advanced (III/IV) Longitudinal Primary + matched mets Pre / Post SOC Pre / Post IO
NSCLC ✓ ✓ ✓ ✓ ✓
CRC ✓ ✓ ✓ ✓ —
Ovarian ✓ ✓ ✓ ✓ —
Breast ✓ ✓ ✓ ✓ —
Gastric ✓ ✓ ✓ ✓ —
Head & Neck SCC ✓ ✓ ✓ ✓ ✓
Prostate (mCRPC) ✓ ✓ — ✓ —
Endometrial ✓ ✓ ✓ ✓ —
Pancreatic ADC ✓ — — ✓ —
Bladder (UC) ✓ ✓ ✓ ✓ —
Melanoma ✓ ✓ ✓ ✓ ✓
RCC ✓ ✓ ✓ ✓ ✓
HCC ✓ ✓ ✓ ✓ —
Esophageal ✓ ✓ ✓ ✓ —

All cohorts are available as FFPE, TMA, or slides. Treatment, response, OS/PFS data and indication-specific molecular characterization (IHC and mutation panels) are linked at the patient level.

04 / 14

A repository purpose-built for translational medicine in oncology.

Standardized, sample-linked, anonymized patient, clinical, and molecular data — in-depth where translational science needs depth.

  • Anonymized and sample-linked — anonymized before it enters our collection and linked to physical specimen(s) in our repository.
  • Standardized data scope reflects what translational programs actually need to make decisions.
  • Specimens behind the records — the underlying tissue is available for re-staining, re-extraction, or re-characterization.
  • IHC, NGS, RNA-Seq, RNAScope, DSP, and digital image analysis — orthogonal testing without stitching across vendors.
  • Expand the molecular profile — additional panel sequencing on the same blocks as markers of interest emerge.
  • Same patients, new questions — the data set extends with the program, without re-sourcing.
05 / 14

A core partner for translational programs.

Why top pharma and biotechs working on oncology therapeutics work with us.

  • The translational bar has moved. Sponsors developing oncology therapeutics need high-quality samples paired with in-depth, standardized data across EHR and orthogonal sources.
  • Defensible data drives defensible programs. Programs only land when the quality of the samples and the rigor of the data behind them can stand up to scrutiny.
  • Validation for regulators. Data derived from TriStar samples is frequently included in IND submissions — tissue quality and annotation rigor shape what is defensible.
  • Validation for the program. Translational evidence is increasingly what investment committees and partnership negotiations anchor on.
  • Sponsors come when the data has to hold up. The story behind a program is only as good as the substrate underneath it.
06 / 14

Digital delivery.

How cohorts arrive in your environment.

Magnification

40×

Standard scan resolution across the repository.

Scanners

Aperio GT450 & AT2

Whole-slide imaging on the same platforms used in clinical practice.

File format

.svs

Pyramidal whole-slide files compatible with all major WSI viewers and AI pipelines.

Cloud handoff

Box / AWS / Azure

Box Enterprise by default, or direct delivery to your customer-managed cloud.

07 / 14

Lab capabilities & orthogonal ground truth.

The lab attached to your records — for validation, extension, and characterization on the same patients.

100+ Optimized IHC assays
Developed for
  • Ventana Benchmark
  • Dako Auto stainers
3 Medical pathologists 15+ combined years in pharma
Services
  • IHC
  • RNAScope
  • NGS
  • RNA-Seq
  • Digital Spatial Profiling
  • Digital image analysis
08 / 14

Advanced disease (Stage III/IV) surgical samples

Tumor types

NSCLC CRC Ovarian Prostate (mCRPC) Breast Gastric Endometrial Pancreatic ADC Bladder (UC) Melanoma RCC HCC Esophageal Head & Neck SCC

Follow-up data

Treatment Response OS/PFS

Mutations*

KRAS NRAS EGFR ALK BRAF BRCA MET HRD

* as available from donor records

IHC markers

ER/PR Her2 MMR MSI PDL-1 TROP2 Nectin4 B7H3 B7H4 DLL3 p16 p53

HBS formats

FFPE TMA Slides
09 / 14

Sequentially collected (longitudinal) surgical samples from the same donor

Tumor types

NSCLC CRC Ovarian Head & Neck SCC Breast Gastric Endometrial RCC Bladder (UC) Melanoma

Follow-up data

Treatment Response OS/PFS

Mutations*

KRAS NRAS EGFR ALK BRAF BRCA MET HRD

* as available from donor records

IHC markers

ER/PR Her2 MMR MSI PDL-1 TROP2 Nectin4 B7H3 B7H4 DLL3 p16 p53

HBS formats

FFPE TMA Slides
11 / 14

Example — Longitudinal NSCLC patient trajectories.

Per-patient. Per matched metastasis. Treatment-line resolved. Examples below are anonymized records from the repository.

Patient #001 Immunotherapy: NoTreatment status: Treatment naïve
  1. Primary specimen Surgery: Left lung upper lobectomy and lymph node sampling Site: Lung, left upper lobe
  2. Matched met 1 Site: Superficial cerebrum and dura Treatment: Immunotherapy naïve
Patient #002 Immunotherapy: NoTreatment status: Treatment naïve
  1. Primary specimen Surgery: Left Thoracotomy and upper lobectomy with wedge of the lower lobe taken en bloc. Sleeve resection of PA Site: Left lung, upper lobe
  2. Matched met 1 Site: Lymph node Treatment: Treatment naïve
  3. Matched met 2 Site: Lymph node Surgery date: Q1-2018 Treatment: Treatment naïve
Patient #007 Immunotherapy: No
  1. Matched met 1 Site: Lymph node Treatment: Treatment naïve
  2. Matched met 2 Site: Lymph node Treatment: Treatment naïve
  3. Matched met 3 Site: Hilar Lymph node Surgery date: Q1-2022 Treatment: Treatment naive Block #: C7
Explore the full dataset
11 / 14

Primary & matched distant metastases (surgical samples)

Tumor types

NSCLC CRC Ovarian Head & Neck SCC Breast Gastric Endometrial Bladder (UC) Melanoma RCC

Examples of metastatic sites

Lymph nodes Bone Liver Lung Brain Peritoneal

*Mets only (without matched primary) samples available

Follow-up data

Treatment Response OS/PFS

Mutations*

KRAS NRAS EGFR ALK BRAF BRCA MET HRD

*As available from donor records.

IHC markers

ER/PR Her2 MMR MSI PDL-1 TROP2 Nectin4 B7H3 B7H4 DLL3 p16 p53

HBS formats

FFPE Slides TMA Block or slides
12 / 14

Pre & Post standard of care (SOC) treatment surgical samples

Includes a sub-set of donor matched sets.

Tumor types

NSCLC CRC Ovarian Head & Neck SCC Breast Gastric Endometrial Pancreatic ADC Bladder (UC) Melanoma RCC

Follow-up data

Treatment Response OS/PFS

Mutations*

KRAS NRAS EGFR ALK BRAF BRCA MET HRD

* as available from donor records

IHC markers

ER/PR Her2 MMR MSI PDL-1 TROP2 Nectin4 B7H3 B7H4 DLL3 p16 p53

HBS formats

FFPE TMA Slides
13 / 14

Pre & Post IO (Pembro/Nivo) treatment surgical samples

1st line SOC chemo, 2nd line IO. Includes a sub-set of donor matched sets.

Tumor types

NSCLC RCC Head & Neck SCC Melanoma

Follow-up data

Treatment Response OS/PFS

Mutations*

KRAS NRAS EGFR ALK BRAF BRCA MET HRD

* as available from donor records

IHC markers

ER/PR Her2 MMR MSI PDL-1 TROP2 Nectin4 B7H3 B7H4 DLL3 p16 p53

HBS formats

FFPE Slides TMA Block or slides